Skip to main content
Top
Published in: Journal of Neurology 6/2016

01-06-2016 | Original Communication

Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes

Authors: H. A. Jinnah, Emily Goodmann, Ami R. Rosen, Marian Evatt, Alan Freeman, Stewart Factor

Published in: Journal of Neurology | Issue 6/2016

Login to get access

Abstract

Botulinum toxin (BoNT) is highly effective in the treatment of cervical dystonia (CD), yet a significant proportion of patients report low levels of satisfaction following treatment and fail to follow up for repeated treatments. The goal of this study was to determine the reasons that some patients have unsatisfactory responses. A total of 35 subjects who came to our center requesting alternative treatments due to unsatisfactory responses following BoNT treatment for CD were evaluated. Included were 26 women and 9 men with an average age of 57.1 years (range 25–82 years), and an average duration of illness of 12.5 years (range 1–55 years). Details of unsatisfactory BoNT treatments were methodically collected by a movement specialist using a standardized intake form, including provider subspecialty, product used, the number of satisfactory or unsatisfactory trials, doses given, specific muscles treated, the use of electromyographic guidance, side effects, and tests of resistance. The specialist then provided repeat treatments if indicated, and followed each case until the reasons for unsatisfactory outcomes could be determined. Multiple reasons for unsatisfactory outcomes were found. They included suboptimal BoNT doses, suboptimal muscle targeting, intolerable side effects, complex movement patterns, discordant perceptions, and incorrect diagnoses. Only one patient was functionally resistant to BoNT. Of 32 subjects who received repeat BoNT treatments, 25 (78 %) achieved satisfactory responses after revision of the original treatment plan. These results indicate that the majority of unsatisfactory responses to BoNT treatment of CD were caused by correctible factors and imply a need for improved education regarding optimal treatment methods.
Literature
1.
go back to reference Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77–100 Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77–100
2.
3.
go back to reference Hallett M, Albanese A, Dressler D et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114CrossRefPubMed Hallett M, Albanese A, Dressler D et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114CrossRefPubMed
4.
go back to reference Albanese A, Abbruzzese G, Dressler D et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213CrossRefPubMedPubMedCentral Albanese A, Abbruzzese G, Dressler D et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213CrossRefPubMedPubMedCentral
5.
go back to reference Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419–423CrossRefPubMed Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419–423CrossRefPubMed
6.
go back to reference Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12:163–170CrossRefPubMed Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12:163–170CrossRefPubMed
8.
go back to reference Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349:84–93CrossRefPubMed Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349:84–93CrossRefPubMed
9.
go back to reference Evidente VG, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov 4:273 Evidente VG, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov 4:273
10.
go back to reference Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293CrossRefPubMed Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293CrossRefPubMed
11.
go back to reference Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19:533–538CrossRefPubMed Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19:533–538CrossRefPubMed
12.
go back to reference Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W (2000) Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15:150–153CrossRefPubMed Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W (2000) Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15:150–153CrossRefPubMed
13.
go back to reference Gill CE, Manus ND, Pelster MW et al (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins (Basel) 5:776–783CrossRef Gill CE, Manus ND, Pelster MW et al (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins (Basel) 5:776–783CrossRef
15.
go back to reference Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360CrossRefPubMed Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360CrossRefPubMed
16.
go back to reference Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213–218CrossRefPubMed Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213–218CrossRefPubMed
17.
go back to reference Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S (2015) Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism Relat Disord 21:111–115CrossRefPubMed Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S (2015) Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism Relat Disord 21:111–115CrossRefPubMed
18.
go back to reference Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27:225–230PubMedPubMedCentral Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27:225–230PubMedPubMedCentral
20.
go back to reference Coleman C, Hubble J, Schwab J, Beffy JL, Picaut P, Morte C (2012) Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA. Int J Neurosci 122:358–362CrossRefPubMed Coleman C, Hubble J, Schwab J, Beffy JL, Picaut P, Morte C (2012) Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA. Int J Neurosci 122:358–362CrossRefPubMed
21.
go back to reference Ruiz PJ, Castrillo JC, Burguera JA et al (2011) Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258:1055–1057CrossRefPubMed Ruiz PJ, Castrillo JC, Burguera JA et al (2011) Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258:1055–1057CrossRefPubMed
22.
go back to reference Fabbri M, Leodori G, Fernandes RM et al (2015) Neutralizing antibody and Botulinum toxin therapy: A systematic review and meta-analysis. Neurotox Res (in press) Fabbri M, Leodori G, Fernandes RM et al (2015) Neutralizing antibody and Botulinum toxin therapy: A systematic review and meta-analysis. Neurotox Res (in press)
23.
go back to reference Svetel M, Pekmezovic T, Tomic A, Kresojevic N, Kostic VS (2015) The spread of primary late-onset focal dystonia in a long-term follow up study. Clin Neurol Neurosurg 132:41–43CrossRefPubMed Svetel M, Pekmezovic T, Tomic A, Kresojevic N, Kostic VS (2015) The spread of primary late-onset focal dystonia in a long-term follow up study. Clin Neurol Neurosurg 132:41–43CrossRefPubMed
24.
go back to reference Jahanshahi M, Marion MH, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47:548–552CrossRefPubMed Jahanshahi M, Marion MH, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47:548–552CrossRefPubMed
25.
go back to reference Martino D, Berardelli A, Abbruzzese G et al (2012) Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. Mov Disord 27:1447–1450CrossRefPubMed Martino D, Berardelli A, Abbruzzese G et al (2012) Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. Mov Disord 27:1447–1450CrossRefPubMed
26.
go back to reference Svetel M, Pekmezovic T, Jovic J et al (2007) Spread of primary dystonia in relation to initially affected region. J Neurol 254:879–883CrossRefPubMed Svetel M, Pekmezovic T, Jovic J et al (2007) Spread of primary dystonia in relation to initially affected region. J Neurol 254:879–883CrossRefPubMed
27.
go back to reference Weiss EM, Hershey T, Karimi M et al (2006) Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 21:1175–1181CrossRefPubMed Weiss EM, Hershey T, Karimi M et al (2006) Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 21:1175–1181CrossRefPubMed
28.
go back to reference Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ (1991) Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 29:370–376CrossRefPubMed Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ (1991) Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 29:370–376CrossRefPubMed
30.
go back to reference Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C (2008) Anterocollis: clinical features and treatment options. Med Sci Monit 14:CR427–CR430PubMed Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C (2008) Anterocollis: clinical features and treatment options. Med Sci Monit 14:CR427–CR430PubMed
31.
go back to reference Jinnah HA, Berardelli A, Comella C et al (2013) The focal dystonias: current views and challenges for future research. Mov Disord 7:926–943CrossRef Jinnah HA, Berardelli A, Comella C et al (2013) The focal dystonias: current views and challenges for future research. Mov Disord 7:926–943CrossRef
32.
34.
go back to reference Bhidayasiri R (2011) Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 17(Suppl 1):S20–S24CrossRefPubMed Bhidayasiri R (2011) Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 17(Suppl 1):S20–S24CrossRefPubMed
35.
go back to reference Glass GA, Ku S, Ostrem JL, Heath S, Larson PS (2009) Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord 15:610–613CrossRefPubMed Glass GA, Ku S, Ostrem JL, Heath S, Larson PS (2009) Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord 15:610–613CrossRefPubMed
36.
go back to reference Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, Group IIC (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2(3):e000881CrossRefPubMedPubMedCentral Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, Group IIC (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2(3):e000881CrossRefPubMedPubMedCentral
37.
go back to reference Flowers JM, Hicklin LA, Marion MH (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26:2409–2414CrossRefPubMed Flowers JM, Hicklin LA, Marion MH (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26:2409–2414CrossRefPubMed
38.
go back to reference Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35:215–223CrossRefPubMed Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35:215–223CrossRefPubMed
Metadata
Title
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes
Authors
H. A. Jinnah
Emily Goodmann
Ami R. Rosen
Marian Evatt
Alan Freeman
Stewart Factor
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 6/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8136-x

Other articles of this Issue 6/2016

Journal of Neurology 6/2016 Go to the issue

Pioneers in Neurology

Ian Bruce Sneddon (1915–1987)